文献速递慢阻肺

Spiration瓣膜系统改善重度异质性肺气肿肺功能:EMPROVE多中心开放标签随机对照试验

Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

EMPROVE试验将172例重度异质性肺气肿患者按2:1随机分为Spiration瓣膜系统(SVS)联合医疗管理组(113例)和单纯医疗管理组(59例)。6个月时SVS组FEV1较对照组显著改善,组间差异0.101 L(95% BCI 0.060-0.141),12个月差异0.099 L(95% BCI 0.048-0.151)。SVS组6个月内复合胸部严重不良事件发生率更高(31.0% vs 11.9%),主要因严重气胸发生率12.4%。

要点

  • SVS联合医疗管理可显著改善重度异质性肺气肿患者6个月和12个月的FEV1。
  • 6个月时除6分钟步行距离外,所有次要疗效终点均显著改善。
  • SVS组复合胸部严重不良事件发生率较高,严重气胸发生率达12.4%。

核心结论

  • 在重度异质性肺气肿患者中,SVS在多项疗效结局上显示显著改善,且安全性可接受。

研究设计与样本

  • 多中心、开放标签、随机对照试验,2013年10月至2017年5月纳入172例40岁及以上重度异质性肺气肿患者,按2:1随机分为SVS联合医疗管理组(n=113)和单纯医疗管理组(n=59)。
  • 男性占53.5%,平均年龄67.4岁。

主要发现

  • 主要疗效终点为基线至6个月平均FEV1差异,治疗组与对照组6个月组间差异为0.101 L(95% BCI 0.060-0.141),12个月为0.099 L(95% BCI 0.048-0.151)。
  • 6个月时治疗组除6分钟步行距离外,所有次要疗效终点均显示统计学显著改善。
  • 6个月内复合胸部严重不良事件发生率治疗组为31.0%,对照组为11.9%,主要因严重气胸发生率为12.4%。

临床怎么用

  • 对于重度异质性肺气肿患者,SVS可作为改善肺功能的多项疗效结局的非手术介入选择,但需权衡严重气胸等不良事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Less invasive, nonsurgical approaches are needed to treat severe emphysema.Objectives: To evaluate the effectiveness and safety of the Spiration Valve System (SVS) versus optimal medical management.Methods: In this multicenter, open-label, randomized, controlled trial, subjects aged 40 years or older with severe, heterogeneous emphysema were randomized 2:1 to SVS with medical management (treatment) or medical management alone (control).Measurements and Main Results: The primary efficacy outcome was the difference in mean FEV1 from baseline to 6 months. Secondary effectiveness outcomes included: difference in FEV1 responder rates, target lobe volume reduction, hyperinflation, health status, dyspnea, and exercise capacity. The primary safety outcome was the incidence of composite thoracic serious adverse events. All analyses were conducted by determining the 95% Bayesian credible intervals (BCIs) for the difference between treatment and control arms. Between October 2013 and May 2017, 172 participants (53.5% male; mean age, 67.4 yr) were randomized to treatment (n = 113) or control (n = 59). Mean FEV1 showed statistically significant improvements between the treatment and control groups-between-group difference at 6 and 12 months, respectively, of 0.101 L (95% BCI, 0.060-0.141) and 0.099 L (95% BCI, 0.048-0.151). At 6 months, the treatment group had statistically significant improvements in all secondary endpoints except 6-minute-walk distance. Composite thoracic serious adverse event incidence through 6 months was greater in the treatment group (31.0% vs. 11.9%), primarily due to a 12.4% incidence of serious pneumothorax.Conclusions: In patients with severe heterogeneous emphysema, the SVS shows significant improvement in multiple efficacy outcomes, with an acceptable safety profile.Clinical trial registered with www.clinicaltrials.gov (NCT01812447).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Criner GJ, Delage A, Voelker K, et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2019. PMID: 31365298. doi:10.1164/rccm.201902-0383OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。